latest
Market/Novel Tech Articles

Roche acquisition of Spark Therapeutics continues to build gene therapy market

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) recently announced the completion of the acquisition of the gene therapy company, following regulatory approval from government authorities. Roche’s $4.8 billion acquisition of Spark was a 64% increase from its initial $2.7 billion offer in what turned out to be a two-way […]

Read full story

NanoDimension and Novartis Venture Fund invest CHF 8 million for optogenetic retinal gene therapies

NanoDimension, a venture capital company in Lausanne, and Novartis Venture Fund in Basel, have launched a new ophthalmology company, Arctos Ltd., to develop viral vector technology for the restoration of eyesight on several ophthalmic indications.  NanoDimension has led the round of CHF 6 million while the balance of the funding will be provided by the […]

Read full story

Limelight Bio has reported a $75M investment focused on a lead gene-therapy ocular program

Limelight Bio, a new biopharmaceutical company, located closely to the University of Pennsylvania’s Centre for Advanced Retinal and Ocular Therapies (CAROT), has raised $75M equity. The company will be focused on the development of gene therapy technologies to build treatments for ophthalmic disorders and several other markets.  The company will be funded by Apple Tree […]

Read full story

Related Market/Novel Tech News